SCHEMBL22736024

SCHEMBL22736024

O=C(CC(c1ccc(-n2cc(-c3ccnc4[nH]cnc34)cn2)nc1)C(F)(F)F)N1CCOCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 1/20 0.36
▸ PKM P14618 2/20 0.34
▸ GCG P01275 1/20 0.33
▸ CCNC P24863 2/20 0.33
▸ CDK8 P49336 2/20 0.33
▸ AURKA O14965 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ DCTPP1 Q9H773 1/20 0.33
▸ JAK1 P23458 3/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ USP7 Q93009 4/20 0.32
▸ JAK2 O60674 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ HDAC1 Q13547 1/20 0.32
▸ HDAC8 Q9BY41 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29567579 0.87 MAPK1 (0.38) GRM4CCNCCDK8MAPK1
SCHEMBL22736009 0.87 MAPK1 (0.38) GRM4CCNCCDK8MAPK1
SCHEMBL29480587 0.86 GRM4 (0.35) GRM4GCGCCNCCDK8JAK1
SCHEMBL22736186 0.85 MAPK1 (0.42) GRM4CCNCCDK8MAPK1
SCHEMBL29567713 0.85 MAPK1 (0.42) GRM4CCNCCDK8MAPK1
SCHEMBL22736494 0.84 JAK2 (0.34) GRM4GCGJAK1JAK2
SCHEMBL29480601 0.84 JAK2 (0.34) GRM4GCGJAK1JAK2
SCHEMBL22736480 0.84 JAK2 (0.34) GRM4GCGJAK1JAK2
SCHEMBL22736497 0.84 JAK2 (0.34) GRM4GCGJAK1JAK2
SCHEMBL29567482 0.84 JAK2 (0.34) GRM4GCGJAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP claimed
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed
WO-2020240586-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 GRM4 2623/4885PKM 2023/4885GCG 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback